Sitemap
- Home
- Neurology
- Rare Disease
- Fabry
- Articles
- Global reach of over 20 years experience in the patient-centered Fabry Registry
- Fabrazyme® (agalsidase beta) safety profile
- Fabrazyme® (agalsidase beta) evidence
- Screening strategies in Fabry disease
- Fabry disease Pathophysiology
- Understanding Fabry disease
- Recognising Fabry disease in Clinical Practice
- Fabry disease and the cardio-renal axis
- Screening Strategies
- Evolving role of AI in the diagnosis of Fabry disease
- Understanding the impact of Fabrazyme (agalsidase beta) on long-term renal function
- Learning from the Canadian Fabry Disease Initiative
- Quantifying the effect of Fabrazyme (agalsidase beta) on the preservation of renal function in Fabry disease
- Articles
- Gaucher
- Pompe
- Articles
- Nexviadyme®▼ (avalglucosidase alfa) safety profile
- Nexviadyme®▼ (avalglucosidase alfa) evidence
- Treatment and Specialist Treatment Centres in the UK for Pompe disease
- Signs and Symptoms of Pompe disease
- What is Pompe disease?
- Managing transition of paediatric Pompe patients to adult services
- How Nexviadyme®▼ (avalglucosidase alfa) was designed
- Our commitment to rare disease
- Why we developed Nexviadyme®▼ (avalglucosidase alfa)
- Testing and Diagnosis of Pompe disease
- Resources
- Articles
- Better Care for Rare
- Articles
- Adopting big data & artificial intelligence to advance diagnosis for rare diseases
- Better Care for Rare
- Fulfilling priorities in England Rare Disease Framework. How can we make them a reality?
- Supporting Real-World Evidence Generation: Rare Disease Registries
- Supporting the rare disease community
- Antonio Ochoa-Ferraro, Specialist Pharmacist in Inherited Metabolic Disease
- Dr Alex Broomfield, Consultant in Inherited Metabolic Diseases at GOSH
- Dr Karolina Stepien, Consultant in Metabolic Medicine at Salford Royal Hospital
- Articles
- Other Rare Disease Topics
- Fabry
- Other Topics
- Cardiology
- Dyslipidaemia
- Articles
- Praluent® (alirocumab) Administration
- Therapeutic indications for Praluent® (alirocumab)
- Specific characteristics of Praluent® (alirocumab)
- NICE and SMC Guidance Praluent® (alirocumab)
- ODYSSEY OUTCOMES Safety Profile Praluent® (alirocumab)
- ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (20 MINUTES)
- ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (2 MINUTES)
- ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (1 HOUR)
- ODYSSEY OUTCOMES Efficacy Praluent® (alirocumab)
- ODYSSEY OUTCOMES Trial Design Praluent® (alirocumab)
- Praluent® (alirocumab) mechanism of action
- Dosing options – customise your patient’s treatment with Praluent® (alirocumab)
- Praluent® (alirocumab) PubExplainer
- A cardiologist's view - Professor Azfar Zaman
- Cardiovascular outcomes for diabetes patients Praluent® (alirocumab)
- FH I & FH II Studies Praluent® (alirocumab)
- Unmet Needs in Dyslipidaemia
- Resources
- Education
- The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS
- Implementing Artificial Intelligence to Risk Stratify, Manage and Refer Patients
- New Approaches and Innovation in Lipid Services – Strengthening the Relationship between Primary and Secondary Care
- Strengthening the Interface Between Primary and Secondary Care
- What's the Future of Secondary Care Lipid Services?
- Articles
- Thrombosis
- Dyslipidaemia
- Diabetes
- Type 2 Diabetes
- Articles
- Head to Head Studies
- Benefits of switching to Toujeo (insulin glargine 300 Units/mL) through patient case studies and patient reported outcomes
- Explore Toujeo (insulin glargine 300 Units/mL) data from the pivotal randomised controlled clinical trials
- Head to Head Studies
- ORION Observational Study
- Video: BRIGHT study
- Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T2DM
- Toujeo (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T2DM
- Events
- Education
- Diabetes UK 2024: Connecting the Dots: Benefits of pen connectivity for people living with diabetes
- Diabetes UK 2024: Navigating Hyperglycaemia after GLP-1s with Insulin
- Diabetes UK 2024: Sustainably scripting tomorrow with Sanofi's Planet Cares Programme and Pen Recycling pilot
- London Symposium 2023: Diet and lipid management: What's new?
- What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes
- London Symposium 2023: Improving outcomes in pregnancies complicated by diabetes
- London Symposium 2023: Latest developments: Kidney disease in diabetes
- Practicalities of Supporting the Teenager With Type 2 Diabetes
- London Symposium 2023: The perils of youth onset Type 2 Diabetes
- Diabetes Podcast Series | Toujeo® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL)
- London Symposium 2023: Should hypoglcaemia risk guide insulin choice in Type 1 and Type 2 diabetes?
- London Symposium 2023: What's new in diabetes psychology?
- Diabetes UK 2023: Cultural humility in diabetes consultation
- Articles
- Type 1 Diabetes
- Articles
- Resources
- Education
- What the InRange Study Can Teach Us About Time-In-Range (TIR)
- London Symposium 2023: Keeping up with exercise in diabetes
- RCT Evidence on Time-In-Range in Type 1 Diabetes
- Diabetes UK 2023: Diabetes & Exercise Masterclass: supporting your patients with Type 1 diabetes on a MDI and CGM with their exercise goals
- Diabetes UK 2023: Multifactorial approach to diabetes management
- London Symposium 2023: Technology update: Implementation of NICE guidance
- Type 2 Diabetes
- Transplant
- Dermatology
- Vaccines
- Oncology
- Other Oncology Topics
- Multiple Myeloma
- Articles
- About Multiple Myeloma
- A Real World Case Study : Presented by Dr Karthik Ramasamy
- A Real World Case Study : Presented by Dr Jane Clark
- A Real World Case Study : Presented by Dr Kenny Douglas
- Overview of the safety and efficacy data from ICARIA-MM Trial
- Independent UK Real World Data. Data from 107 patients from 24 centres across the UK.
- A Real World Case Study : Presented by Dr Ceri Bygrave
- Resources
- Articles
- Products
- Admelog® (insulin lispro 100 units/ml (GB ONLY))
- Aldurazyme® (laronidase)
- Avaxim® (hepatitis A vaccine (inactivated, adsorbed))
- Avaxim® Junior (hepatitis A vaccine (inactivated, adsorbed))
- Cerdelga®▼ (hard capsules eliglustat)
- Cerezyme® (imiglucerase for injection)
- Clexane® (enoxaparin)
- Dupixent® (dupilumab) Atopic Dermatitis
- Dupixent® (dupilumab) Prurigo Nodularis
- Fabrazyme® (agalsidase beta)
- Lantus® (insulin glargine 100 units/mL)
- Lemtrada® (alemtuzumab)
- MenQuadfiTM▼ (meningococcal (group A,C,W,Y) conjugate vaccine)
- Myozyme® (alglucosidase alfa)
- Nexviadyme®▼ (avalglucosidase alfa) (GB only)
- Praluent® (alirocumab)
- Quadrivalent Influenza Vaccine (split virion, inactivated)
- Quadrivalent Influenza Vaccine▼ Split Virion, Inactivated High-Dose (QIV-HD)
- Repevax® (diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content))
- Revaxis® (diphtheria, tetanus & poliomyelitis (inactivated) vaccine (absorbed, reduced antigen(s) content))
- Rezurock®▼ (belumosudil) tablets (GB ONLY)
- SARCLISA®▼ (isatuximab) (GB ONLY)
- Stamaril® (yellow fever vaccine (live))
- Supemtek▼ (quadrivalent influenza vaccine (recombinant, prepared in cell culture))
- Toujeo® (insulin glargine 300 units/ml)
- Trurapi®▼ (insulin aspart 100 units/mL)
- Typhim Vi® (typhoid polysaccharide vaccine)
- Vaxelis® (diphtheria, Tetanus, Pertussis (acellular, component), Hepatitis B (rDNA), Poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed))
- Verorab® Inactivated Rabies Vaccines
- Viatim® Hepatitis A (inactivated, adsorbed) and Typhoid polysaccharide vaccine
- Therapeutic Areas
- Articles
- Resources
- Tools
- Events
- Education
- Sign In
- Sign Up
- Sitemap
- Terms of Use
- Privacy Policy
- Cookie Policy